Halozyme Therapeutics has entered into a global collaboration and licence agreement with Incyte to develop subcutaneous formulations of INCA033989, a monoclonal antibody for mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms (MPNs), using Halozyme’s ENHANZE® drug delivery technology.

• Technology Integration: ENHANZE® uses Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20) enzyme technology to enable subcutaneous delivery of injectable therapies and support more convenient dosing regimens.
• Agreement Scope: Incyte receives rights to develop and commercialise ENHANZE® for its mutCALR programme, with options to nominate up to two additional therapeutic targets. Halozyme will receive an upfront payment, milestone-based payments, and tiered royalties on future commercial sales.
• Clinical Application: The collaboration aims to develop more convenient subcutaneous treatment options for patients with mutCALR-expressing myeloproliferative neoplasms, potentially reducing treatment burden while supporting ongoing clinical development.

This summary is based on a press release issued by Halozyme Therapeutics, Inc.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.